Brevan Howard Capital Management LP Increases Position in Hologic, Inc. $HOLX

Brevan Howard Capital Management LP raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 163.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 46,737 shares of the medical equipment provider’s stock after buying an additional 29,009 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Hologic were worth $3,154,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Cinctive Capital Management LP raised its stake in shares of Hologic by 53.4% during the 3rd quarter. Cinctive Capital Management LP now owns 66,404 shares of the medical equipment provider’s stock worth $4,482,000 after acquiring an additional 23,119 shares in the last quarter. Bank of Nova Scotia grew its holdings in Hologic by 355.5% in the third quarter. Bank of Nova Scotia now owns 116,456 shares of the medical equipment provider’s stock worth $7,860,000 after purchasing an additional 90,888 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Hologic during the third quarter worth $433,000. Aquatic Capital Management LLC acquired a new position in shares of Hologic during the third quarter worth $1,730,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Hologic during the 3rd quarter valued at $1,089,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Finally, BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Stock Up 0.0%

Hologic stock opened at $75.15 on Tuesday. The stock has a market capitalization of $16.78 billion, a PE ratio of 31.31, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.75. The business has a 50 day simple moving average of $75.14 and a 200-day simple moving average of $72.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business earned $0.87 EPS. The business’s revenue was up 2.5% compared to the same quarter last year. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.